Migraine Med Shows Weight-Loss Benefit
Atogepant, an FDA-approved migraine medication, has shown potential for significant weight loss in patients with obesity. In a study, nearly one-third of participants experienced a weight reduction of 5% or more after one year of consistent use. Experts caution that while the findings are promising, further research is needed to confirm the weight loss effects across similar medications.
- ▪Atogepant is an oral CGRP receptor antagonist approved for migraine prevention.
- ▪In a study, 34.9% of participants achieved at least 5% weight reduction after one year.
- ▪The study involved 279 adults with episodic and chronic migraine and a BMI ≥ 25.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/migraine-med-shows-weight-loss-benefit-2026a1000dm5?src=rss |
| Publication time | Wed, 29 Apr 2026 05:17:24 EDT |
| Retrieval time | 2026-04-29T09:36:54.536Z |
| Last seen | 2026-04-29T09:36:54.536Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 8UFUnwdvVuWt |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
CHICAGO — Atogepant (Qulipta, AbbVie), an oral, calcitonin gene-related peptide (CGRP) receptor antagonist FDA-approved for the prevention of migraine, may do more than reduce headache frequency — it may also drive meaningful weight loss in patients with overweight or obesity.In an open-label extension study, nearly one third of patients consistently taking atogepant 60 mg once daily experienced a 5% or greater weight reduction over 1 year of treatment, with about 13% having 10% or greater weight loss.For weight loss, patients “must take the 60 mg dose and they must take it consistently over time,” said Jessica Ailani, MD, director of the Medstar Georgetown Headache Center, Washington, DC.The study was presented on April 21 at the American Academy of Neurology (AAN) 2026 Annual…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
